ATM and glioma: For solid tumors, crizotinib + dasatinib in low-grade glioma (87% responders; active in 16 cancer types) and AZD0156 (ATM/ATRi) plus olaparib (PARPi) in Ewing's sarcoma (84% responders; active in 16 cancer types) were high scoring (Fig. 2E; Supplementary Table S8).